At ASNR 2025, Neurophet showcased Neurophet AQUA AD, a cutting-edge AI solution designed to support the diagnosis and treatment monitoring of Alzheimer’s disease. This software uses machine learning algorithms to analyze MRI and PET brain imaging, offering quantitative biomarkers that assist in tracking disease progression and treatment effects. Specifically tailored for anti-amyloid therapies, AQUA AD enables clinicians and researchers to detect imaging abnormalities, including Amyloid-Related Imaging Abnormalities (ARIA), with precision.

During the Industry Collaboration Session, Neurophet’s Co-CEO Jake Junkil Been highlighted how AQUA AD is already being used in real-world settings to support prescription decisions and monitor adverse effects of Alzheimer’s treatments such as Leqembi and Kisunla. The software’s compatibility with clinical imaging workflows and its ability to deliver accurate, repeatable results make it a valuable tool for pharmaceutical companies conducting clinical trials. Its adoption is increasing among institutions needing reliable imaging analytics to ensure therapy safety and efficacy.

Neurophet’s participation in ASNR 2025 signals its commitment to advancing neuroimaging AI on the global stage. By demonstrating the clinical utility of AQUA AD, the company is not only promoting its technological leadership but also facilitating strategic partnerships with leading pharmaceutical firms and academic researchers. As the demand for ARIA monitoring and neurodegenerative disease management grows, Neurophet AQUA AD positions itself as a crucial tool for improving outcomes in Alzheimer's care and broader brain health diagnostics.

MedTech Spectrum's Summary

Innovative AI-powered imaging analysis: Neurophet AQUA AD uses advanced machine learning to quantitatively analyze MRI and PET scans, enabling precise monitoring of Alzheimer’s disease treatment and detection of Amyloid-Related Imaging Abnormalities (ARIA).

Clinical application in Alzheimer’s treatment: The software supports prescription decisions and safety monitoring during anti-amyloid antibody therapies like Leqembi and Kisunla, aiding pharmaceutical companies and medical institutions in managing treatment outcomes effectively.

Critical role in improving patient care: By providing reliable, quantitative neuroimaging biomarkers, AQUA AD enhances treatment monitoring and prognosis prediction, addressing the growing global need for accurate brain disorder diagnostics and advancing Alzheimer’s disease management.